Clinical publications

Ebixa is a moderate affinity, uncompetitive NMDA receptor antagonist.

Clinical Experience Ebixa is a moderate affinity, uncompetitive NMDA receptor antagonist. In this section you can explore the unique features of Ebixa. Click on your area of interest from the list below to read more.

Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial

Pomara N, Ott BR, Peskind E, Resnick EM. Alzheimer Dis Assoc Disord 2007; 21(1):60-64

Memantine in Moderate to Severe Alzheimer's Disease: a Meta-Analysis of Randomised Clinical Trials

Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ Dement Geriatr Cogn Disord 2007; 24(1):20-27

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment

Cummings JL, Schneider E, Tariot PN, Graham SM Neurology 2006; 67(1):57-63.

Meta-analysis of six-month memantine trials in AD

Doody R. Alzheimer's & Dementia 3, 7-17. 2007. Ref Type: Generic

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease

Jones RW, Bayer A, Inglis F, Barker A, Phul R. Int J Geriatr Psychiatry 2007; 22(3):258-262

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease

Ott BR, Blake LM, Kagan E, Resnick M. J Neurol 2007; 254(3):351-358

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment

Feldman HH, Schmitt FA, Olin JT. Alzheimer Dis Assoc Disord 2006; 20(4):263-268

Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis

Schmitt FA, van Dyck CH, Wichems CH, Olin JT. Alzheimer Dis Assoc Disord 2006; 20(4):255-262

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

Gauthier S, Wirth Y, Mobius HJ. Int J Geriatr Psychiatry 2005; 20(5):459-464

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ Arch Neurol 2006; 63(1):49-54

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. JAMA 2004; 291(3):317-324.

Memantine in moderate-to-severe Alzheimer's disease

Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. N Engl J Med 2003; 348(14):1333-1341.

Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial

Peskind ER, Potkin SG, Pomara N et al. Am J Geriatr Psychiatry 2006.

A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease

van Dyck CH, Tariot PN, Meyers B, Malca RE. Alzheimer Dis Assoc Disord 2007; 21(2):136-143.

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

Winblad B, Poritis N Int J Geriatr Psychiatry 1999; 14(2):135-146.

Last updated: 03.09.2007

Key publications

Clinical publications

Pre-clinical

Literature Search

PubMed
Google Scholar